The data is being presented this week at the 2026 Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Boston, including one oral presentation and two poster presentations, as well as one oral presentation at TIDES USA 2026: Oligonucleotide and Peptide Therapeutics Conference.

Key EDIT-401 data presented include:

  • In an oral presentation at ASGCT, Editas reported that a single dose of EDIT-401 achieved ≥90 percent mean LDL-C reduction across all dose groups in non-human primates (NHPs).
    • ≥90 percent mean LDL-C reduction was achieved with only moderate levels (10-40 percent) of functional editing of LDLR alleles and ≥6-fold mean increase in hepatic LDLR protein.
    • LDL-C lowering was rapid and remained durable across evaluated dose levels (1.5 mg/kg-3.0 mg/kg) through ~6 months.
    • Promising preclinical safety profile with no adverse clinical observations at therapeutically relevant dose (1.5 mg/kg).
    • The highest delivery of EDIT-401 was observed in the hepatocytes as compared to other non-target tissues with undetectable oocyte delivery.
  • In an oral presentation at TIDES, Editas presented data demonstrating EDIT-401 dose-dependent LDL-C reduction in NHPs.
  • In a poster presentation at ASGCT, Editas reported that data evaluating pharmacokinetics and pharmacodynamics of a single dose of EDIT-401(mu) across multiple dose levels in heterozygous Ldlr loss-of-function mice and wildtype mice support that dose adjustments may not be needed to achieve LDL-C lowering in Heterozygous Familial Hypercholesterolemia (HeFH) patients.

     

Additional in vivo upregulation findings from a poster presentation at ASGCT include:

  • Data support leveraging DNA large language prediction models (DNA-LLM) to accelerate and streamline the pursuit of gene editing-based strategies designed to mitigate disease through augmentation of alternate or compensatory pathways and further highlight the broader potential of Editas' in vivo gene upregulation platform.

     

"These new EDIT-401 preclinical data, including durability of LDL-C reduction across a range of doses through ~6 months demonstrated in NHPs, strengthen our confidence in EDIT-401 as a potential one-time treatment to deliver meaningful and durable LDL-C lowering and support its continued advancement toward first-in-human clinical development," said Linda C. Burkly, Ph.D., Executive Vice President and Chief Scientific Officer, Editas Medicine. "Further, the data presented also highlight the broader potential and differentiation of our upregulation strategy to generate new medicines across multiple disease areas."

The presentation details are listed below. Abstracts can be accessed on the ASGCT website, and the presentations will be posted on the Editas Medicine website during the conferences.

American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting, May 11-15

Oral Presentation:

Title: Preclinical Development of EDIT-401, a Durable In Vivo CRISPR Gene Editing Therapy That Upregulates LDLR Protein to Lower LDL-C

Session Date and Time: Thursday, May 14, 3:30 p.m. – 5:00 p.m. EDT

Session Title: Gene Therapy for Cardiovascular Diseases  

Presentation Room: 206AB 

Final Abstract Number: 380 

Poster Presentations:

Title: Pharmacokinetics and Pharmacodynamics of In Vivo Gene Editing Therapy for Lowering LDL-C in Mice

Session Date and Time: Thursday, May 14, 5:00 p.m. – 6:30 p.m. EDT  

Session Title: Thursday Poster Reception  

Presentation Room: Exhibit and Poster Hall  

Final Abstract Number: 3423  

Title: In Vivo CRISPR-based Disruption of an Important Gene Repressor Element Upregulates a Compensatory Protein to Normalize Disease-Associated Biomarkers in a Knockout Mouse Disease Model

Session Date and Time: Wednesday, May 13, 5:00 p.m. – 6:30 p.m. EDT  

Session Title: Wednesday Poster Reception

Presentation Room: Exhibit and Poster Hall  

Final Abstract Number: 2324

TIDES USA 2026: Oligonucleotide and Peptide Therapeutics Conference, May 11-14

Oral Presentation:

Title: Transformative LDL Cholesterol Lowering In Vivo CRISPR Gene Editing Approach for Hyperlipidemia and Atherosclerotic Cardiovascular Disease

Session Date and Time: Wednesday, May 13, 8:30 a.m. – 9:00 a.m. EDT

Session Title: mRNA & Genome Editing: Technology & Applications